Kidney Cancer

Vision - To eliminate kidney cancer through collaboration and discovery

According to the American Cancer Society approximately 63,990 new cases of kidney cancer will occur in the U.S. and 14,400 people will die from the disease. The most common form of kidney cancer, renal cell carcinoma (RCC), is the most lethal of urologic cancers, with approximately 35% of patients dying from the disease. Incidence rates for RCC have risen steadily each year during the last three decades in most of the world, with an average increase of 2% to 3% per year. Kidney cancer research has been funded by the CDMRP for many years under various programs, including the Peer Reviewed Medical Research Program, Tuberous Sclerosis Complex Research Program, and most recently, the Peer Reviewed Cancer Research Program (PRCRP). From fiscal year 2010 (FY10) through FY16, the PRCRP invested $9.8 million (M) in kidney cancer research. In FY17 the U.S. Congress directed $10M to kidney cancer research in the DoD appropriation, thus establishing the Kidney Cancer Research Program (KCRP). With a new program, the KCRP will be able to focus on the issues regarding prevention, detection, treatment, and the long-term effects of treatment for kidney cancer for Service Members, Veterans, their families, and the American public.

About Us The CDMRP originated in 1992 via a Congressional appropriation to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders-the American public, the military, and Congress.

Your browser does not support scripts, you have to enable it to run this page